US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib
Dr. Sudhir Manda presents the US MM-6 study, a community-based study looking at long-term proteasome inhibition in multiple myeloma (MM) following an in-class transition from bortezomib (btz) to ixazomib (ixa).
Dr. Manda gives a detailed account of the trial design, results, and the ongoing enrollment status of this clinical trial. He finalizes by explaining what clinical and patient impact this research will have.